Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:108a
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 108A
Character Range: 52483–55998

108A  Vaccine                                                                                                                                                                                                                                                                                Nimenrix           Injection (0.5mL)                                                                 After reconstitution, each of the following:                                                                                                                                                                                                                                                                                                                   1 dose
      Meningococcal polysaccharide serogroups A, C, W‑135 and Y conjugate                                                                                                                                                                                                                                                                                                                             (a) Meningococcal polysaccharide ‑ Serogroup A[1] — 5 μg                                                                                                                                                                                                                                                                                                   If in circumstances (c), (d) or (e): 2 to 4 doses of a primary course plus booster doses as described in subsection 7(1A)
      Circumstances                                                                                                                                                                                                                                                                                                                                                                                   (b) Meningococcal polysaccharide ‑ Serogroup C1 — 5 μg
      Vaccine may be provided to:                                                                                                                                                                                                                                                                                                                                                                     (c) Meningococcal polysaccharide ‑ Serogroup W‑1351 — 5 μg
       (a) a child who is 12 months old; or                                                                                                                                                                                                                                                                                                                                                           (d) Meningococcal polysaccharide ‑ Serogroup Y1 —  5 μg
       (b) a person who is at least 14 years old but less than 20 years of age; or
       (c) a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or
       (d) a person who has complement deficiency; or
       (e) a person undergoing eculizumab treatment; or
       (f) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab.